Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]

Affiliations

• ¹ Dana-Farber/Partners CancerCare, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
• ² Exelixis Inc., South San Francisco, CA, USA.
• ³ Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
• ⁴ Alliance Statistics and Data Center, Duke University, Durham, NC, USA.
• ⁵ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
• ⁶ Alliance Protocol Operations Office, Chicago, IL, USA.
• ⁷ Dana-Farber/Partners CancerCare, Boston, MA, USA.
• ⁸ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
• ⁹ Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
• ¹⁰ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
• ¹¹ University of Kansas - Wichita, Wichita, KS, USA.
• ¹² Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ¹³ Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.